Man Chiu Poon

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. pmc Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China
    Runhui Wu
    Department of Haematology, Beijing Children s Hospital and Capital Medical University, Beijing, China
    Health Qual Life Outcomes 10:112. 2012
  2. doi request reprint Hemophilia management in transfusion medicine
    Man Chiu Poon
    The Department of Medicine and The Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
    Transfus Apher Sci 46:299-307. 2012
  3. doi request reprint 2B or not to be--the 45-year saga of the Montreal Platelet Syndrome
    Man Chiu Poon
    Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Thromb Haemost 104:903-10. 2010
  4. ncbi request reprint The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders
    Man Chiu Poon
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Transfus Med Rev 21:223-36. 2007
  5. ncbi request reprint Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
  6. ncbi request reprint Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents
    Man Chiu Poon
    University of Calgary, Southern Alberta Hemophilia Clinic, Calgary Health Region, Canada
    Semin Hematol 43:S33-6. 2006
  7. ncbi request reprint Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey
    M C Poon
    Centre d Hémophiles, AP HP Hôpital Bicêtre, Le Kremlin Bicetre, France
    J Thromb Haemost 2:1096-103. 2004
  8. ncbi request reprint Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group
    M C Poon
    Department of Medicine, University of Calgary and Foothills Hospital, Alberta, Canada
    Blood Coagul Fibrinolysis 11:S55-68. 2000
  9. ncbi request reprint Use of recombinant factor VIIa in hereditary bleeding disorders
    M C Poon
    Division of Hematology and Hematologic Malignancies, Department of Medicine, Southern Alberta Hemophilia Clinic, University of Calgary, Alberta, Canada
    Curr Opin Hematol 8:312-8. 2001
  10. ncbi request reprint Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Man Chiu Poon
    Foothills Medical Centre, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada
    Curr Hematol Rep 2:139-47. 2003

Detail Information

Publications26

  1. pmc Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China
    Runhui Wu
    Department of Haematology, Beijing Children s Hospital and Capital Medical University, Beijing, China
    Health Qual Life Outcomes 10:112. 2012
    ..Quality of life (QoL) is increasingly recognized as an important outcome measure in clinical trials. The Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) shows promise for use in China...
  2. doi request reprint Hemophilia management in transfusion medicine
    Man Chiu Poon
    The Department of Medicine and The Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
    Transfus Apher Sci 46:299-307. 2012
    ....
  3. doi request reprint 2B or not to be--the 45-year saga of the Montreal Platelet Syndrome
    Man Chiu Poon
    Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Thromb Haemost 104:903-10. 2010
    ..This paper will review the 45-year saga of Montreal Platelet Syndrome, a story that highlights the value of revisiting a rare diagnosis to look for a more common explanation...
  4. ncbi request reprint The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders
    Man Chiu Poon
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Transfus Med Rev 21:223-36. 2007
    ..For GT patients undergoing surgery and for treatment and prevention of bleeding in thrombocytopenic patients, the optimal rFVIIa regimen remains to be defined...
  5. ncbi request reprint Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
    M C Poon
    Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
    Blood 94:3951-3. 1999
    ..No adverse effects of rFVIIa were observed. Although the number of patients is small, our study suggests that rFVIIa may be an alternative to platelet transfusions in patients with a severe congenital thrombocytopathy...
  6. ncbi request reprint Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents
    Man Chiu Poon
    University of Calgary, Southern Alberta Hemophilia Clinic, Calgary Health Region, Canada
    Semin Hematol 43:S33-6. 2006
    ..glanzmann-reg.org) data collection tool. Data collection will begin in 2005 and continue for up to 6 years. Patients of all ages from any country are eligible for inclusion...
  7. ncbi request reprint Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey
    M C Poon
    Centre d Hémophiles, AP HP Hôpital Bicêtre, Le Kremlin Bicetre, France
    J Thromb Haemost 2:1096-103. 2004
    ..Anecdotal reports suggest recombinant factor (rF)VIIa might be a therapeutic alternative in these situations...
  8. ncbi request reprint Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group
    M C Poon
    Department of Medicine, University of Calgary and Foothills Hospital, Alberta, Canada
    Blood Coagul Fibrinolysis 11:S55-68. 2000
    ..Analysis of data from this larger population will allow better comprehension of the role of NovoSeven in these disorders, and assist in the design of formal studies to address issues associated with the treatment of these disorders...
  9. ncbi request reprint Use of recombinant factor VIIa in hereditary bleeding disorders
    M C Poon
    Division of Hematology and Hematologic Malignancies, Department of Medicine, Southern Alberta Hemophilia Clinic, University of Calgary, Alberta, Canada
    Curr Opin Hematol 8:312-8. 2001
    ..With expanding indications and more widespread use, thromboembolic complications must be carefully monitored, especially in patients at risk for thromboembolism. The high cost of this drug may be a limiting factor...
  10. ncbi request reprint Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Man Chiu Poon
    Foothills Medical Centre, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada
    Curr Hematol Rep 2:139-47. 2003
    ..If rFVIIa is used, unresolved issues include optional dosage, dosing interval, and whether rFVIIa is best used alone or in conjunction with platelet transfusion...
  11. ncbi request reprint Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study
    Man Chiu Poon
    University of Calgary, Alberta, Canada
    Thromb Haemost 87:431-5. 2002
    ..No other serious adverse events, including thrombotic episodes, were reported. To the best of our knowledge, this is the first formal report of recovery and inhibitor formation on rFIX in a peer-reviewed manuscript form...
  12. ncbi request reprint Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia
    M C Poon
    Hemophilia Hemostasis Centres in Canada
    Semin Hematol 38:21-5. 2001
    ....
  13. ncbi request reprint Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
    Russell D Hull
    University of Calgary, Calgary, Alta, Canada
    Am J Med 119:1062-72. 2006
    ..Low-molecular-weight heparin, body-weight adjusted, avoids anticoagulant monitoring and has been shown to be more effective than vitamin-K-antagonist therapy...
  14. doi request reprint The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation
    Shannon C Jackson
    Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada
    Blood 113:3348-51. 2009
    ..Thus, in reevaluating this kindred, we determined that patients with MPS have type 2B VWD with the V1316M VWF mutation...
  15. ncbi request reprint Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature
    Shannon Jackson
    Division of Hematology, Department of Medicine, University of Calgary, Alberta, Canada
    Am J Hematol 78:142-50. 2005
    ..Large randomized-controlled studies enrolling patients from various ethnic backgrounds will be necessary to determine the response rate and mechanism of response and to gain a better understanding of the pathogenesis of ITP...
  16. pmc 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    Tom Bowen
    Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
    Allergy Asthma Clin Immunol 6:24. 2010
    ....
  17. pmc Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia
    Man Chiu Poon
    Department of Medicine, University of Calgary, Alberta, Canada
    Vasc Health Risk Manag 3:655-64. 2007
    ..This more "optimal regimen" derived from a recent International Survey needs confirmation with larger studies. What the optimal regimen for surgical coverage is remains unresolved...
  18. ncbi request reprint Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome
    Russell D Hull
    University of Calgary, Calgary, AB, Canada
    Am J Med 122:762-769.e3. 2009
    ..Home-LITE compared long-term treatment at home with tinzaparin or usual care in terms of efficacy, safety, patients' treatment satisfaction, incidence of post-thrombotic syndrome, and associated venous leg ulcers...
  19. ncbi request reprint Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin Titusville
    Rebecca Deyell
    Department of Pediatrics, University of Calgary and Calgary Health Region, Calgary, AB, Canada
    J Pediatr Hematol Oncol 28:100-2. 2006
    ..Early recognition of abnormal hemoglobin variants in asymptomatic patients may avoid extensive, unnecessary medical investigations...
  20. doi request reprint Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal
    Dar Dowlatshahi
    Department of Medicine, Division of Neurology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa Hospital Civic Campus, Room C2182, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9
    Stroke 43:1812-7. 2012
    ..Given the lack of randomized controlled trial evidence of efficacy, and the potential for thrombotic complications, we aimed to determine outcomes in patients with aaICH treated with PCC...
  21. doi request reprint Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura
    Shannon C Jackson
    Division of Hematology, Department of Medicine, Foothills Medical Centre, 1403 29th Street N W, Calgary, AB, T2N 2T9, Canada
    Int J Hematol 88:212-8. 2008
    ..Although the prevalence of H. pylori is low, H. pylori positive Canadian patients with ITP may benefit from a trial of H. pylori eradication therapy as a safe and effective means to achieve long term platelet response...
  22. ncbi request reprint Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema
    Tom Bowen
    Department of Medicine and Paediatrics, University of Calgary, Alberta, Canada
    Ann Allergy Asthma Immunol 100:S30-40. 2008
    ..We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004...
  23. ncbi request reprint Case 1-2005: cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease
    Rosaleen Chun
    Department of Anesthesia, Foothills Medical Center, Calgary, Alberta, Canada
    J Cardiothorac Vasc Anesth 19:109-17. 2005
  24. ncbi request reprint Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk
    Denis Cournoyer
    Department of Medicine, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada
    J Am Soc Nephrol 15:2728-34. 2004
    ....
  25. ncbi request reprint Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms
    Russell D Hull
    University of Calgary, Calgary, AB, Canada
    Am J Med 120:72-82. 2007
    ..We evaluated the effectiveness and safety of long-term LMWH compared with vitamin K antagonist therapy in a broad spectrum of patients with proximal vein thrombosis...
  26. ncbi request reprint Aminoglycoside suppression of nonsense mutations in severe hemophilia
    Paula D James
    Department of Medicine, Queen s University, Kingston, Ontario, Canada K7L 3N6
    Blood 106:3043-8. 2005
    ..This study, however, does provide a proof of principle, suggesting that ribosomal interference with a less toxic agent may be a potential therapeutic mechanism for severe hemophilia patients with nonsense mutations...